Feature Story:

FDA approves once-daily MIRAPEX ER for the treatment of early Parkinson’s disease

Ridgefield, CT, February 22, 2010 — Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson’s disease (PD).¹ MIRAPEX ER is not indicated in advanced PD. Parkinson’s disease is a chronic, slowly progressive and potentially debilitating neurological condition² affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.³